Industry Research Reports
Home > Reports > Pharma & Healthcare > Omalizumab Biosimilars- Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032
Omalizumab Biosimilars- Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032
Industry: Pharma & Healthcare
Published Date: 2026-04-16
Pages: 139 Pages
Report ld: 6456595
Request Sample
Customized Report
- Description
- Table of Contents
- Table of Figures
- Related Reports
PDF Download
- Description
- Table of Contents
- Table of Figures
- Related Reports
- PDF Download
Omalizumab Biosimilars Market Size(US$)
CAGR 2026-2032
11.2%
Market Size,2032
USD 598
Million
Market Snapshot
Market Size in 2026 (Value)
US$ 315 million
Market Forecast in 2032(Value)
US$ 598 million
CAGR
11.2%
Years Considered
2021-2032
Base Year
2026
Forecast Period
2026-2032
Source: Secondary research, interviews with experts, and QYResearch analysis
The global market for Omalizumab Biosimilars was estimated to be worth US$ 290 million in 2025 and is projected to reach US$ 598 million, growing at a CAGR of 11.2% from 2026 to 2032.
The potential shifts in the 2025 U.S. tariff framework pose substantial volatility risks to global markets. This report provides a comprehensive assessment of recent tariff adjustments and international strategic countermeasures on Omalizumab Biosimilars cross-border industrial footprints, capital allocation patterns, regional economic interdependencies, and supply chain reconfigurations.
In 2025, global Omalizumab Biosimilars production reached approximately 909 k doses, with an average global market price of around US$ 319 per dose. Gross margin is about 43%. The cost is 182 usd, the production is 1200 k doses. Omalizumab is a medication used to treat asthma, nasal polyps, and urticaria. Omalizumab is a recombinant DNA-derived humanized IgG1k monoclonal antibody that specifically binds to free human immunoglobulin E (IgE) in the blood and interstitial fluid and to membrane-bound form of IgE (mIgE) on the surface of mIgE-expressing B lymphocytes. Unlike an ordinary anti-IgE antibody, it does not bind to IgE that is already bound by the high affinity IgE receptor (FcεRI) on the surface of mast cells, basophils, and antigen-presenting dendritic cells.
The market is entering a rapid commercialization stage
As the first omalizumab biosimilars gain approval in major markets such as Europe and the United States, the market is shifting from development and regulatory preparation to commercialization and competition. More biosimilar manufacturers are expected to enter the market, accelerating adoption and increasing competition.
Price competition will become increasingly important
As more omalizumab biosimilars are launched, price competition is expected to intensify. Lower treatment costs will improve patient access and encourage hospitals, insurers, and healthcare systems to promote biosimilar substitution over the original branded drug.
Interchangeability will become a key competitive advantage
In the United States, interchangeability status is likely to become an important factor influencing market share. Biosimilars with interchangeable designation may gain stronger acceptance from pharmacies, payers, and physicians because they can be substituted more easily for the original product.
More dosage forms and specifications will be introduced
Manufacturers are expected to launch additional dosage strengths, pre-filled syringes, auto-injectors, and patient-friendly packaging formats. Competition will increasingly depend on product portfolios, ease of administration, and compatibility with existing treatment practices.
Expansion of indications will increase long-term market potential
As the original omalizumab product continues to gain approvals for new indications such as food allergy, nasal polyps, and other IgE-mediated diseases, biosimilars are also expected to benefit from a larger addressable market in the future.
This report provides a comprehensive view of the global market for Omalizumab Biosimilars, covering total sales volume, sales revenue, pricing, the market share and ranking of key companies, along with analyses by region & country, by Type, and by Application.
The Omalizumab Biosimilars market size, estimations, and forecasts are presented in terms of sales volume (K Dose) and revenue ($ millions), with 2025 as the base year and historical and forecast data from 2021 to 2032. The report combines quantitative and qualitative analysis to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current marketplace, and make informed business decisions regarding Omalizumab Biosimilars.
MARKET SEGMENTATION
By Company
- Roche
- Novartis
- Glenmark Pharmaceuticals
- Selexis
- Generium
- CuraTeQ
- Celltrion Healthcare
- Alvotech
- BiosanaPharma
- Mabpharm
- CSPC Pharmaceutical Group
- Biomabs
- HisunPharm
Consumption by Region
- North America
- United States
- Canada
- Asia-Pacific
- China
- Japan
- South Korea
- Southeast Asia
- India
- Australia
- Rest of Asia-Pacific
- Europe
- Germany
- France
- U.K.
- Italy
- Netherlands
- Nordic Countries
- Rest of Europe
- Latin America
- Mexico
- Brazil
- Rest of Latin America
- Middle East & Africa
- Turkey
- Saudi Arabia
- UAE
- Rest of MEA
Segment by Type
- 150 mg/mL
- 75 mg/0.5 mL
Segment by Application
- Persistent Asthma
- Nasal Polyps
- Chronic Idiopathic Urticaria
Segment by Category
- For Adults
- For Teenagers
- For Children
Segment by Division
- Every 2 Weeks
- Every 4 Weeks
- Individualized Dosing Regimen
CHAPTER OUTLINE
Chapter 1: Introduces the scope of the report and the global market size (value, volume, and price). It also summarizes market dynamics and Recent Developments; identifies key drivers and restraints; outlines challenges and risks for manufacturers; reviews relevant industry policies and U.S. tariff implications.
Chapter 2: Provides a detailed analysis of the Omalizumab Biosimilars manufacturers' competitive landscape—including pricing, sales and revenue shares, Recent Developments plans, and mergers and acquisitions (M&A).
Chapter 3: Analyzes market segmentation by Type, presenting the size and growth potential of each segment to help readers identify blue-ocean opportunities.
Chapter 4: Analyzes market segmentation by Application, presenting the size and growth potential of each downstream segment to help readers identify blue-ocean opportunities.
Chapter 5: Presents Omalizumab Biosimilars sales and revenue at the regional level. It offers a quantitative assessment of market size and growth potential by region and summarizes market development, future prospects, addressable space, and country-level market size worldwide.
Chapter 6: Presents Omalizumab Biosimilars sales and revenue at the country level. It provides segmented data by Type and by Application for each country/region.
Chapter 7: Profiles key players, detailing the main companies' product sales, revenue, pricing, gross margin, product portfolios, Recent Developments, etc.
Chapter 8: Analyzes the industry value chain, including upstream suppliers and downstream applications/customers.
Chapter 9: Conclusion.
QYRESEARCH'S STRENGTHS
Unlike generic global market reports, this study combines macro-level industry trends with hyper-local operational intelligence, empowering data-driven decisions across the Compound Chocolate value chain, addressing:
Market entry risks/opportunities by region
We identify regional market threats and growth prospects to guide your overseas layout.
Product mix optimization based on local practices
We adjust product portfolios in line with local consumption habits.
Competitor tactics in fragmented vs. consolidated markets
We unpack rivals’ operation strategies for scattered and highly concentrated industries.
Full Research Coverage
We cover competition landscape, full supply chain and quantified market size data, and deliver tailor-made customized surveys to meet your unique business demands.
19 Years Industry Expertise
We own self-owned massive exclusive databases, backed by 19 years of global market research experience across thousands of sectors.
24/7 Fast Report Delivery
Our team operates 24 hours a day, 365 days a year, enabling ultra-fast report turnaround to respond to your research needs efficiently.
Localized Strategic Analysis
We integrate regional risk assessment, localized product optimization and competitor analysis to deliver actionable market strategies.
Market entry risks/opportunities by region
All data is cross-verified from multiple industry sources to deliver thorough, precise analysis that supports reliable corporate strategic decisions.
Market entry risks/opportunities by region
We provide responsive, dedicated after-sales support to resolve all follow-up inquiries about reports, data and industry interpretation.
TABLE OF CONTENTS
1 Market Overview
1.1 Omalizumab Biosimilars Product Introduction
1.2 Global Omalizumab Biosimilars Market Size Forecast
1.2.1 Global Omalizumab Biosimilars Sales Value (2021–2032)
1.2.2 Global Omalizumab Biosimilars Sales Volume (2021–2032)
1.2.3 Global Omalizumab Biosimilars Sales Price (2021–2032)
1.3 Omalizumab Biosimilars Market Trends & Drivers
1.3.1 Omalizumab Biosimilars Industry Trends
1.3.2 Omalizumab Biosimilars Market Drivers & Opportunities
1.3.3 Omalizumab Biosimilars Market Challenges
1.3.4 Omalizumab Biosimilars Market Restraints
1.3.5 Impact of U.S. Tariffs
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global Omalizumab Biosimilars Players Revenue Ranking (2025)
2.2 Global Omalizumab Biosimilars Revenue by Company (2021–2026)
2.3 Global Omalizumab Biosimilars Sales Volume Ranking of Players (2025)
2.4 Global Omalizumab Biosimilars Sales Volume by Company (2021–2026)
2.5 Global Omalizumab Biosimilars Average Price by Company (2021–2026)
2.6 Key Manufacturers Omalizumab Biosimilars Manufacturing Base and Headquarters
2.7 Key Manufacturers Omalizumab Biosimilars Product Offerings
2.8 Key Manufacturers Start of Mass Production of Omalizumab Biosimilars
2.9 Omalizumab Biosimilars Market Competitive Analysis
2.9.1 Omalizumab Biosimilars Market Concentration Rate (2021–2026)
2.9.2 Global 5 and 10 Largest Manufacturers by Omalizumab Biosimilars Revenue in 2025
2.9.3 Global Companies by Tier (Tier 1, Tier 2, Tier 3), based on Omalizumab Biosimilars revenue, 2025
2.10 Mergers & Acquisitions and Expansion
3 Segmentation Omalizumab Biosimilars Market Classification
3.1 Introduction by Type
3.1.1 150 mg/mL
3.1.2 75 mg/0.5 mL
3.1.3 Global Omalizumab Biosimilars Sales Value by Type
3.1.3.1 Global Omalizumab Biosimilars Sales Value by Type (2021 vs 2025 vs 2032)
3.1.3.2 Global Omalizumab Biosimilars Sales Value, by Type (2021–2032)
3.1.3.3 Global Omalizumab Biosimilars Sales Value, by Type (%), 2021–2032
3.1.4 Global Omalizumab Biosimilars Sales Volume by Type
3.1.4.1 Global Omalizumab Biosimilars Sales Volume by Type (2021 vs 2025 vs 2032)
3.1.4.2 Global Omalizumab Biosimilars Sales Volume, by Type (2021–2032)
3.1.4.3 Global Omalizumab Biosimilars Sales Volume, by Type (%), 2021–2032
3.1.5 Global Omalizumab Biosimilars Average Price by Type (2021–2032)
3.2 Introduction by Age
3.2.1 For Adults
3.2.2 For Teenagers
3.2.3 For Children
3.2.4 Global Omalizumab Biosimilars Sales Value by Age
3.2.4.1 Global Omalizumab Biosimilars Sales Value by Age (2021 vs 2025 vs 2032)
3.2.4.2 Global Omalizumab Biosimilars Sales Value, by Age (2021–2032)
3.2.4.3 Global Omalizumab Biosimilars Sales Value, by Age (%), 2021–2032
3.2.5 Global Omalizumab Biosimilars Sales Volume by Age
3.2.5.1 Global Omalizumab Biosimilars Sales Volume by Age (2021 vs 2025 vs 2032)
3.2.5.2 Global Omalizumab Biosimilars Sales Volume, by Age (2021–2032)
3.2.5.3 Global Omalizumab Biosimilars Sales Volume, by Age (%), 2021–2032
3.2.6 Global Omalizumab Biosimilars Average Price by Age (2021–2032)
3.3 Introduction by Frequency
3.3.1 Every 2 Weeks
3.3.2 Every 4 Weeks
3.3.3 Individualized Dosing Regimen
3.3.4 Global Omalizumab Biosimilars Sales Value by Frequency
3.3.4.1 Global Omalizumab Biosimilars Sales Value by Frequency (2021 vs 2025 vs 2032)
3.3.4.2 Global Omalizumab Biosimilars Sales Value, by Frequency (2021–2032)
3.3.4.3 Global Omalizumab Biosimilars Sales Value, by Frequency (%), 2021–2032
3.3.5 Global Omalizumab Biosimilars Sales Volume by Frequency
3.3.5.1 Global Omalizumab Biosimilars Sales Volume by Frequency (2021 vs 2025 vs 2032)
3.3.5.2 Global Omalizumab Biosimilars Sales Volume, by Frequency (2021–2032)
3.3.5.3 Global Omalizumab Biosimilars Sales Volume, by Frequency (%), 2021–2032
3.3.6 Global Omalizumab Biosimilars Average Price by Frequency (2021–2032)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 Persistent Asthma
4.1.2 Nasal Polyps
4.1.3 Chronic Idiopathic Urticaria
4.2 Global Omalizumab Biosimilars Sales Value by Application
4.2.1 Global Omalizumab Biosimilars Sales Value by Application (2021 vs 2025 vs 2032)
4.2.2 Global Omalizumab Biosimilars Sales Value, by Application (2021–2032)
4.2.3 Global Omalizumab Biosimilars Sales Value, by Application (%), 2021–2032
4.3 Global Omalizumab Biosimilars Sales Volume by Application
4.3.1 Global Omalizumab Biosimilars Sales Volume by Application (2021 vs 2025 vs 2032)
4.3.2 Global Omalizumab Biosimilars Sales Volume, by Application (2021–2032)
4.3.3 Global Omalizumab Biosimilars Sales Volume, by Application (%), 2021–2032
4.4 Global Omalizumab Biosimilars Average Price by Application (2021–2032)
5 Segmentation by Region
5.1 Global Omalizumab Biosimilars Sales Value by Region
5.1.1 Global Omalizumab Biosimilars Sales Value by Region: 2021 vs 2025 vs 2032
5.1.2 Global Omalizumab Biosimilars Sales Value by Region (2021–2026)
5.1.3 Global Omalizumab Biosimilars Sales Value by Region (2027–2032)
5.1.4 Global Omalizumab Biosimilars Sales Value by Region (%), 2021–2032
5.2 Global Omalizumab Biosimilars Sales Volume by Region
5.2.1 Global Omalizumab Biosimilars Sales Volume by Region: 2021 vs 2025 vs 2032
5.2.2 Global Omalizumab Biosimilars Sales Volume by Region (2021–2026)
5.2.3 Global Omalizumab Biosimilars Sales Volume by Region (2027–2032)
5.2.4 Global Omalizumab Biosimilars Sales Volume by Region (%), 2021–2032
5.3 Global Omalizumab Biosimilars Average Price by Region (2021–2032)
5.4 North America
5.4.1 North America Omalizumab Biosimilars Sales Value, 2021–2032
5.4.2 North America Omalizumab Biosimilars Sales Value by Country (%), 2025 vs 2032
5.5 Europe
5.5.1 Europe Omalizumab Biosimilars Sales Value, 2021–2032
5.5.2 Europe Omalizumab Biosimilars Sales Value by Country (%), 2025 vs 2032
5.6 Asia Pacific
5.6.1 Asia Pacific Omalizumab Biosimilars Sales Value, 2021–2032
5.6.2 Asia Pacific Omalizumab Biosimilars Sales Value by Region (%), 2025 vs 2032
5.7 South America
5.7.1 South America Omalizumab Biosimilars Sales Value, 2021–2032
5.7.2 South America Omalizumab Biosimilars Sales Value by Country (%), 2025 vs 2032
5.8 Middle East & Africa
5.8.1 Middle East & Africa Omalizumab Biosimilars Sales Value, 2021–2032
5.8.2 Middle East & Africa Omalizumab Biosimilars Sales Value by Country (%), 2025 vs 2032
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions Omalizumab Biosimilars Sales Value Growth Trends, 2021 vs 2025 vs 2032
6.2 Key Countries/Regions Omalizumab Biosimilars Sales Value and Sales Volume
6.2.1 Key Countries/Regions Omalizumab Biosimilars Sales Value, 2021–2032
6.2.2 Key Countries/Regions Omalizumab Biosimilars Sales Volume, 2021–2032
6.3 United States
6.3.1 United States Omalizumab Biosimilars Sales Value, 2021–2032
6.3.2 United States Omalizumab Biosimilars Sales Value by Type (%), 2025 vs 2032
6.3.3 United States Omalizumab Biosimilars Sales Value by Application, 2025 vs 2032
6.4 Europe
6.4.1 Europe Omalizumab Biosimilars Sales Value, 2021–2032
6.4.2 Europe Omalizumab Biosimilars Sales Value by Type (%), 2025 vs 2032
6.4.3 Europe Omalizumab Biosimilars Sales Value by Application, 2025 vs 2032
6.5 China
6.5.1 China Omalizumab Biosimilars Sales Value, 2021–2032
6.5.2 China Omalizumab Biosimilars Sales Value by Type (%), 2025 vs 2032
6.5.3 China Omalizumab Biosimilars Sales Value by Application, 2025 vs 2032
6.6 Japan
6.6.1 Japan Omalizumab Biosimilars Sales Value, 2021–2032
6.6.2 Japan Omalizumab Biosimilars Sales Value by Type (%), 2025 vs 2032
6.6.3 Japan Omalizumab Biosimilars Sales Value by Application, 2025 vs 2032
6.7 South Korea
6.7.1 South Korea Omalizumab Biosimilars Sales Value, 2021–2032
6.7.2 South Korea Omalizumab Biosimilars Sales Value by Type (%), 2025 vs 2032
6.7.3 South Korea Omalizumab Biosimilars Sales Value by Application, 2025 vs 2032
6.8 Southeast Asia
6.8.1 Southeast Asia Omalizumab Biosimilars Sales Value, 2021–2032
6.8.2 Southeast Asia Omalizumab Biosimilars Sales Value by Type (%), 2025 vs 2032
6.8.3 Southeast Asia Omalizumab Biosimilars Sales Value by Application, 2025 vs 2032
6.9 India
6.9.1 India Omalizumab Biosimilars Sales Value, 2021–2032
6.9.2 India Omalizumab Biosimilars Sales Value by Type (%), 2025 vs 2032
6.9.3 India Omalizumab Biosimilars Sales Value by Application, 2025 vs 2032
7 Company Profiles
7.1 Roche
7.1.1 Roche Company Information
7.1.2 Roche Introduction and Business Overview
7.1.3 Roche Omalizumab Biosimilars Sales, Revenue, Price and Gross Margin (2021–2026)
7.1.4 Roche Omalizumab Biosimilars Product Offerings
7.1.5 Roche Recent Developments
7.2 Novartis
7.2.1 Novartis Company Information
7.2.2 Novartis Introduction and Business Overview
7.2.3 Novartis Omalizumab Biosimilars Sales, Revenue, Price and Gross Margin (2021–2026)
7.2.4 Novartis Omalizumab Biosimilars Product Offerings
7.2.5 Novartis Recent Developments
7.3 Glenmark Pharmaceuticals
7.3.1 Glenmark Pharmaceuticals Company Information
7.3.2 Glenmark Pharmaceuticals Introduction and Business Overview
7.3.3 Glenmark Pharmaceuticals Omalizumab Biosimilars Sales, Revenue, Price and Gross Margin (2021–2026)
7.3.4 Glenmark Pharmaceuticals Omalizumab Biosimilars Product Offerings
7.3.5 Glenmark Pharmaceuticals Recent Developments
7.4 Selexis
7.4.1 Selexis Company Information
7.4.2 Selexis Introduction and Business Overview
7.4.3 Selexis Omalizumab Biosimilars Sales, Revenue, Price and Gross Margin (2021–2026)
7.4.4 Selexis Omalizumab Biosimilars Product Offerings
7.4.5 Selexis Recent Developments
7.5 Generium
7.5.1 Generium Company Information
7.5.2 Generium Introduction and Business Overview
7.5.3 Generium Omalizumab Biosimilars Sales, Revenue, Price and Gross Margin (2021–2026)
7.5.4 Generium Omalizumab Biosimilars Product Offerings
7.5.5 Generium Recent Developments
7.6 CuraTeQ
7.6.1 CuraTeQ Company Information
7.6.2 CuraTeQ Introduction and Business Overview
7.6.3 CuraTeQ Omalizumab Biosimilars Sales, Revenue, Price and Gross Margin (2021–2026)
7.6.4 CuraTeQ Omalizumab Biosimilars Product Offerings
7.6.5 CuraTeQ Recent Developments
7.7 Celltrion Healthcare
7.7.1 Celltrion Healthcare Company Information
7.7.2 Celltrion Healthcare Introduction and Business Overview
7.7.3 Celltrion Healthcare Omalizumab Biosimilars Sales, Revenue, Price and Gross Margin (2021–2026)
7.7.4 Celltrion Healthcare Omalizumab Biosimilars Product Offerings
7.7.5 Celltrion Healthcare Recent Developments
7.8 Alvotech
7.8.1 Alvotech Company Information
7.8.2 Alvotech Introduction and Business Overview
7.8.3 Alvotech Omalizumab Biosimilars Sales, Revenue, Price and Gross Margin (2021–2026)
7.8.4 Alvotech Omalizumab Biosimilars Product Offerings
7.8.5 Alvotech Recent Developments
7.9 BiosanaPharma
7.9.1 BiosanaPharma Company Information
7.9.2 BiosanaPharma Introduction and Business Overview
7.9.3 BiosanaPharma Omalizumab Biosimilars Sales, Revenue, Price and Gross Margin (2021–2026)
7.9.4 BiosanaPharma Omalizumab Biosimilars Product Offerings
7.9.5 BiosanaPharma Recent Developments
7.10 Mabpharm
7.10.1 Mabpharm Company Information
7.10.2 Mabpharm Introduction and Business Overview
7.10.3 Mabpharm Omalizumab Biosimilars Sales, Revenue, Price and Gross Margin (2021–2026)
7.10.4 Mabpharm Omalizumab Biosimilars Product Offerings
7.10.5 Mabpharm Recent Developments
7.11 CSPC Pharmaceutical Group
7.11.1 CSPC Pharmaceutical Group Company Information
7.11.2 CSPC Pharmaceutical Group Introduction and Business Overview
7.11.3 CSPC Pharmaceutical Group Omalizumab Biosimilars Sales, Revenue, Price and Gross Margin (2021–2026)
7.11.4 CSPC Pharmaceutical Group Omalizumab Biosimilars Product Offerings
7.11.5 CSPC Pharmaceutical Group Recent Developments
7.12 Biomabs
7.12.1 Biomabs Company Information
7.12.2 Biomabs Introduction and Business Overview
7.12.3 Biomabs Omalizumab Biosimilars Sales, Revenue, Price and Gross Margin (2021–2026)
7.12.4 Biomabs Omalizumab Biosimilars Product Offerings
7.12.5 Biomabs Recent Developments
7.13 HisunPharm
7.13.1 HisunPharm Company Information
7.13.2 HisunPharm Introduction and Business Overview
7.13.3 HisunPharm Omalizumab Biosimilars Sales, Revenue, Price and Gross Margin (2021–2026)
7.13.4 HisunPharm Omalizumab Biosimilars Product Offerings
7.13.5 HisunPharm Recent Developments
8 Industry Chain Analysis
8.1 Omalizumab Biosimilars Industrial Chain
8.2 Omalizumab Biosimilars Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Key Suppliers of Raw Materials
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customer Analysis)
8.5 Sales Model and Sales Channelss
8.5.1 Omalizumab Biosimilars Sales Model
8.5.2 Sales Channels
8.5.3 Omalizumab Biosimilars Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.1.1 Research Programs/Design
10.1.1.2 Market Size Estimation
10.1.1.3 Market Breakdown and Data Triangulation
10.1.2 Data Source
10.1.2.1 Secondary Sources
10.1.2.2 Primary Sources
10.2 Author Details
10.3 Disclaimer
TABLE OF FIGURES
List of Tables
Table 1. Omalizumab Biosimilars Market Trends
Table 2. Omalizumab Biosimilars Market Drivers & Opportunities
Table 3. Omalizumab Biosimilars Market Challenges
Table 4. Omalizumab Biosimilars Market Restraints
Table 5. Global Omalizumab Biosimilars Revenue by Company (US$ Million), 2021–2026
Table 6. Global Omalizumab Biosimilars Revenue Market Share by Company (2021–2026)
Table 7. Global Omalizumab Biosimilars Sales Volume by Company (K Dose), 2021–2026
Table 8. Global Omalizumab Biosimilars Sales Volume Market Share by Company (2021–2026)
Table 9. Global Market Omalizumab Biosimilars Price by Company (US$/Dose), 2021–2026
Table 10. Key Manufacturers Omalizumab Biosimilars Manufacturing Base and Headquarters
Table 11. Key Manufacturers Omalizumab Biosimilars Product Type
Table 12. Key Manufacturers Start of Mass Production of Omalizumab Biosimilars
Table 13. Global Omalizumab Biosimilars Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Top Manufacturers Market Share by Tier (Tier 1, Tier 2, Tier 3), based on Omalizumab Biosimilars revenue, 2025
Table 15. Mergers & Acquisitions and Expansion Plans
Table 16. Global Omalizumab Biosimilars Sales Value by Type: 2021 vs 2025 vs 2032 (US$ Million)
Table 17. Global Omalizumab Biosimilars Sales Value by Type (US$ Million), 2021–2026
Table 18. Global Omalizumab Biosimilars Sales Value by Type (US$ Million), 2027–2032
Table 19. Global Omalizumab Biosimilars Sales Market Share in Value by Type (2021–2026)
Table 20. Global Omalizumab Biosimilars Sales Market Share in Value by Type (2027–2032)
Table 21. Global Omalizumab Biosimilars Sales Volume by Type: 2021 vs 2025 vs 2032 (K Dose)
Table 22. Global Omalizumab Biosimilars Sales Volume by Type (K Dose), 2021–2026
Table 23. Global Omalizumab Biosimilars Sales Volume by Type (K Dose), 2027–2032
Table 24. Global Omalizumab Biosimilars Sales Market Share in Volume by Type (2021–2026)
Table 25. Global Omalizumab Biosimilars Sales Market Share in Volume by Type (2027–2032)
Table 26. Global Omalizumab Biosimilars Price by Type (US$/Dose), 2021–2026
Table 27. Global Omalizumab Biosimilars Price by Type (US$/Dose), 2027–2032
Table 28. Global Omalizumab Biosimilars Sales Value by Age: 2021 vs 2025 vs 2032 (US$ Million)
Table 29. Global Omalizumab Biosimilars Sales Value by Age (US$ Million), 2021–2026
Table 30. Global Omalizumab Biosimilars Sales Value by Age (US$ Million), 2027–2032
Table 31. Global Omalizumab Biosimilars Sales Market Share in Value by Age (2021–2026)
Table 32. Global Omalizumab Biosimilars Sales Market Share in Value by Age (2027–2032)
Table 33. Global Omalizumab Biosimilars Sales Volume by Age: 2021 vs 2025 vs 2032 (K Dose)
Table 34. Global Omalizumab Biosimilars Sales Volume by Age (K Dose), 2021–2026
Table 35. Global Omalizumab Biosimilars Sales Volume by Age (K Dose), 2027–2032
Table 36. Global Omalizumab Biosimilars Sales Market Share in Volume by Age (2021–2026)
Table 37. Global Omalizumab Biosimilars Sales Market Share in Volume by Age (2027–2032)
Table 38. Global Omalizumab Biosimilars Price by Age (US$/Dose), 2021–2026
Table 39. Global Omalizumab Biosimilars Price by Age (US$/Dose), 2027–2032
Table 40. Global Omalizumab Biosimilars Sales Value by Frequency: 2021 vs 2025 vs 2032 (US$ Million)
Table 41. Global Omalizumab Biosimilars Sales Value by Frequency (US$ Million), 2021–2026
Table 42. Global Omalizumab Biosimilars Sales Value by Frequency (US$ Million), 2027–2032
Table 43. Global Omalizumab Biosimilars Sales Market Share in Value by Frequency (2021–2026)
Table 44. Global Omalizumab Biosimilars Sales Market Share in Value by Frequency (2027–2032)
Table 45. Global Omalizumab Biosimilars Sales Volume by Frequency: 2021 vs 2025 vs 2032 (K Dose)
Table 46. Global Omalizumab Biosimilars Sales Volume by Frequency (K Dose), 2021–2026
Table 47. Global Omalizumab Biosimilars Sales Volume by Frequency (K Dose), 2027–2032
Table 48. Global Omalizumab Biosimilars Sales Market Share in Volume by Frequency (2021–2026)
Table 49. Global Omalizumab Biosimilars Sales Market Share in Volume by Frequency (2027–2032)
Table 50. Global Omalizumab Biosimilars Price by Frequency (US$/Dose), 2021–2026
Table 51. Global Omalizumab Biosimilars Price by Frequency (US$/Dose), 2027–2032
Table 52. Global Omalizumab Biosimilars Sales Value by Application: 2021 vs 2025 vs 2032 (US$ Million)
Table 53. Global Omalizumab Biosimilars Sales Value by Application (US$ Million), 2021–2026
Table 54. Global Omalizumab Biosimilars Sales Value by Application (US$ Million), 2027–2032
Table 55. Global Omalizumab Biosimilars Sales Market Share in Value by Application (2021–2026)
Table 56. Global Omalizumab Biosimilars Sales Market Share in Value by Application (2027–2032)
Table 57. Global Omalizumab Biosimilars Sales Volume by Application: 2021 vs 2025 vs 2032 (K Dose)
Table 58. Global Omalizumab Biosimilars Sales Volume by Application (K Dose), 2021–2026
Table 59. Global Omalizumab Biosimilars Sales Volume by Application (K Dose), 2027–2032
Table 60. Global Omalizumab Biosimilars Sales Market Share in Volume by Application (2021–2026)
Table 61. Global Omalizumab Biosimilars Sales Market Share in Volume by Application (2027–2032)
Table 62. Global Omalizumab Biosimilars Price by Application (US$/Dose), 2021–2026
Table 63. Global Omalizumab Biosimilars Price by Application (US$/Dose), 2027–2032
Table 64. Global Omalizumab Biosimilars Sales Value by Region, (US$ Million), 2021 vs 2025 vs 2032
Table 65. Global Omalizumab Biosimilars Sales Value by Region (US$ Million), 2021–2026
Table 66. Global Omalizumab Biosimilars Sales Value by Region (US$ Million), 2027–2032
Table 67. Global Omalizumab Biosimilars Sales Value by Region (%), 2021–2026
Table 68. Global Omalizumab Biosimilars Sales Value by Region (%), 2027–2032
Table 69. Global Omalizumab Biosimilars Sales Volume by Region (K Dose): 2021 vs 2025 vs 2032
Table 70. Global Omalizumab Biosimilars Sales Volume by Region (K Dose), 2021–2026
Table 71. Global Omalizumab Biosimilars Sales Volume by Region (K Dose), 2027–2032
Table 72. Global Omalizumab Biosimilars Sales Volume by Region (%), 2021–2026
Table 73. Global Omalizumab Biosimilars Sales Volume by Region (%), 2027–2032
Table 74. Global Omalizumab Biosimilars Average Price by Region (US$/Dose), 2021–2026
Table 75. Global Omalizumab Biosimilars Average Price by Region (US$/Dose), 2027–2032
Table 76. Key Countries/Regions Omalizumab Biosimilars Sales Value Growth Trends, (US$ Million): 2021 vs 2025 vs 2032
Table 77. Key Countries/Regions Omalizumab Biosimilars Sales Value, (US$ Million), 2021–2026
Table 78. Key Countries/Regions Omalizumab Biosimilars Sales Value, (US$ Million), 2027–2032
Table 79. Key Countries/Regions Omalizumab Biosimilars Sales Volume, (K Dose), 2021–2026
Table 80. Key Countries/Regions Omalizumab Biosimilars Sales Volume, (K Dose), 2027–2032
Table 81. Roche Company Information
Table 82. Roche Introduction and Business Overview
Table 83. Roche Omalizumab Biosimilars Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021–2026)
Table 84. Roche Omalizumab Biosimilars Product Offerings
Table 85. Roche Recent Developments
Table 86. Novartis Company Information
Table 87. Novartis Introduction and Business Overview
Table 88. Novartis Omalizumab Biosimilars Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021–2026)
Table 89. Novartis Omalizumab Biosimilars Product Offerings
Table 90. Novartis Recent Developments
Table 91. Glenmark Pharmaceuticals Company Information
Table 92. Glenmark Pharmaceuticals Introduction and Business Overview
Table 93. Glenmark Pharmaceuticals Omalizumab Biosimilars Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021–2026)
Table 94. Glenmark Pharmaceuticals Omalizumab Biosimilars Product Offerings
Table 95. Glenmark Pharmaceuticals Recent Developments
Table 96. Selexis Company Information
Table 97. Selexis Introduction and Business Overview
Table 98. Selexis Omalizumab Biosimilars Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021–2026)
Table 99. Selexis Omalizumab Biosimilars Product Offerings
Table 100. Selexis Recent Developments
Table 101. Generium Company Information
Table 102. Generium Introduction and Business Overview
Table 103. Generium Omalizumab Biosimilars Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021–2026)
Table 104. Generium Omalizumab Biosimilars Product Offerings
Table 105. Generium Recent Developments
Table 106. CuraTeQ Company Information
Table 107. CuraTeQ Introduction and Business Overview
Table 108. CuraTeQ Omalizumab Biosimilars Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021–2026)
Table 109. CuraTeQ Omalizumab Biosimilars Product Offerings
Table 110. CuraTeQ Recent Developments
Table 111. Celltrion Healthcare Company Information
Table 112. Celltrion Healthcare Introduction and Business Overview
Table 113. Celltrion Healthcare Omalizumab Biosimilars Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021–2026)
Table 114. Celltrion Healthcare Omalizumab Biosimilars Product Offerings
Table 115. Celltrion Healthcare Recent Developments
Table 116. Alvotech Company Information
Table 117. Alvotech Introduction and Business Overview
Table 118. Alvotech Omalizumab Biosimilars Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021–2026)
Table 119. Alvotech Omalizumab Biosimilars Product Offerings
Table 120. Alvotech Recent Developments
Table 121. BiosanaPharma Company Information
Table 122. BiosanaPharma Introduction and Business Overview
Table 123. BiosanaPharma Omalizumab Biosimilars Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021–2026)
Table 124. BiosanaPharma Omalizumab Biosimilars Product Offerings
Table 125. BiosanaPharma Recent Developments
Table 126. Mabpharm Company Information
Table 127. Mabpharm Introduction and Business Overview
Table 128. Mabpharm Omalizumab Biosimilars Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021–2026)
Table 129. Mabpharm Omalizumab Biosimilars Product Offerings
Table 130. Mabpharm Recent Developments
Table 131. CSPC Pharmaceutical Group Company Information
Table 132. CSPC Pharmaceutical Group Introduction and Business Overview
Table 133. CSPC Pharmaceutical Group Omalizumab Biosimilars Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021–2026)
Table 134. CSPC Pharmaceutical Group Omalizumab Biosimilars Product Offerings
Table 135. CSPC Pharmaceutical Group Recent Developments
Table 136. Biomabs Company Information
Table 137. Biomabs Introduction and Business Overview
Table 138. Biomabs Omalizumab Biosimilars Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021–2026)
Table 139. Biomabs Omalizumab Biosimilars Product Offerings
Table 140. Biomabs Recent Developments
Table 141. HisunPharm Company Information
Table 142. HisunPharm Introduction and Business Overview
Table 143. HisunPharm Omalizumab Biosimilars Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021–2026)
Table 144. HisunPharm Omalizumab Biosimilars Product Offerings
Table 145. HisunPharm Recent Developments
Table 146. Key Raw Materials Lists
Table 147. Key Suppliers of Raw Materials Lists
Table 148. Omalizumab Biosimilars Downstream Customers
Table 149. Omalizumab Biosimilars Distributors List
Table 150. Research Programs/Design for This Report
Table 151. Key Data Information from Secondary Sources
Table 152. Key Data Information from Primary Sources
List of Figures
Figure 1. Omalizumab Biosimilars Product Picture
Figure 2. Global Omalizumab Biosimilars Sales Value, 2021 vs 2025 vs 2032 (US$ Million)
Figure 3. Global Omalizumab Biosimilars Sales Value (US$ Million), 2021–2032
Figure 4. Global Omalizumab Biosimilars Sales Volume (K Dose), 2021–2032
Figure 5. Global Omalizumab Biosimilars Sales Price (US$/Dose), 2021–2032
Figure 6. Omalizumab Biosimilars Report Years Considered
Figure 7. Global Omalizumab Biosimilars Players Revenue Ranking (US$ Million), 2025
Figure 8. Global Omalizumab Biosimilars Sales Volume Ranking of Players (K Dose), 2025
Figure 9. The 5 and 10 Largest Manufacturers in the World: Market Share by Omalizumab Biosimilars Revenue in 2025
Figure 10. Omalizumab Biosimilars Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2021 vs 2025
Figure 11. 150 mg/mL Picture
Figure 12. 75 mg/0.5 mL Picture
Figure 13. Global Omalizumab Biosimilars Sales Value by Type (US$ Million), 2021 vs 2025 vs 2032
Figure 14. Global Omalizumab Biosimilars Sales Value Market Share by Type, 2025 & 2032
Figure 15. Global Omalizumab Biosimilars Sales Volume by Type (K Dose), 2021 vs 2025 vs 2032
Figure 16. Global Omalizumab Biosimilars Sales Volume Market Share by Type, 2025 & 2032
Figure 17. Global Omalizumab Biosimilars Price by Type (US$/Dose), 2021–2032
Figure 18. For Adults Picture
Figure 19. For Teenagers Picture
Figure 20. For Children Picture
Figure 21. Global Omalizumab Biosimilars Sales Value by Age (US$ Million), 2021 vs 2025 vs 2032
Figure 22. Global Omalizumab Biosimilars Sales Value Market Share by Age, 2025 & 2032
Figure 23. Global Omalizumab Biosimilars Sales Volume by Age (K Dose), 2021 vs 2025 vs 2032
Figure 24. Global Omalizumab Biosimilars Sales Volume Market Share by Age, 2025 & 2032
Figure 25. Global Omalizumab Biosimilars Price by Age (US$/Dose), 2021–2032
Figure 26. Every 2 Weeks Picture
Figure 27. Every 4 Weeks Picture
Figure 28. Individualized Dosing Regimen Picture
Figure 29. Global Omalizumab Biosimilars Sales Value by Frequency (US$ Million), 2021 vs 2025 vs 2032
Figure 30. Global Omalizumab Biosimilars Sales Value Market Share by Frequency, 2025 & 2032
Figure 31. Global Omalizumab Biosimilars Sales Volume by Frequency (K Dose), 2021 vs 2025 vs 2032
Figure 32. Global Omalizumab Biosimilars Sales Volume Market Share by Frequency, 2025 & 2032
Figure 33. Global Omalizumab Biosimilars Price by Frequency (US$/Dose), 2021–2032
Figure 34. Product Picture of Persistent Asthma
Figure 35. Product Picture of Nasal Polyps
Figure 36. Product Picture of Chronic Idiopathic Urticaria
Figure 37. Global Omalizumab Biosimilars Sales Value by Application (US$ Million), 2021 vs 2025 vs 2032
Figure 38. Global Omalizumab Biosimilars Sales Value Market Share by Application, 2025 & 2032
Figure 39. Global Omalizumab Biosimilars Sales Volume by Application (K Dose), 2021 vs 2025 vs 2032
Figure 40. Global Omalizumab Biosimilars Sales Volume Market Share by Application, 2025 & 2032
Figure 41. Global Omalizumab Biosimilars Price by Application (US$/Dose), 2021–2032
Figure 42. North America Omalizumab Biosimilars Sales Value (US$ Million), 2021–2032
Figure 43. North America Omalizumab Biosimilars Sales Value by Country (%), 2025 vs 2032
Figure 44. Europe Omalizumab Biosimilars Sales Value (US$ Million), 2021–2032
Figure 45. Europe Omalizumab Biosimilars Sales Value by Country (%), 2025 vs 2032
Figure 46. Asia Pacific Omalizumab Biosimilars Sales Value (US$ Million), 2021–2032
Figure 47. Asia Pacific Omalizumab Biosimilars Sales Value by Region (%), 2025 vs 2032
Figure 48. South America Omalizumab Biosimilars Sales Value (US$ Million), 2021–2032
Figure 49. South America Omalizumab Biosimilars Sales Value by Country (%), 2025 vs 2032
Figure 50. Middle East & Africa Omalizumab Biosimilars Sales Value (US$ Million), 2021–2032
Figure 51. Middle East & Africa Omalizumab Biosimilars Sales Value by Country (%), 2025 vs 2032
Figure 52. Key Countries/Regions Omalizumab Biosimilars Sales Value (%), 2021–2032
Figure 53. Key Countries/Regions Omalizumab Biosimilars Sales Volume (%), 2021–2032
Figure 54. United States Omalizumab Biosimilars Sales Value (US$ Million), 2021–2032
Figure 55. United States Omalizumab Biosimilars Sales Value by Type (%), 2025 vs 2032
Figure 56. United States Omalizumab Biosimilars Sales Value by Application (%), 2025 vs 2032
Figure 57. Europe Omalizumab Biosimilars Sales Value (US$ Million), 2021–2032
Figure 58. Europe Omalizumab Biosimilars Sales Value by Type (%), 2025 vs 2032
Figure 59. Europe Omalizumab Biosimilars Sales Value by Application (%), 2025 vs 2032
Figure 60. China Omalizumab Biosimilars Sales Value (US$ Million), 2021–2032
Figure 61. China Omalizumab Biosimilars Sales Value by Type (%), 2025 vs 2032
Figure 62. China Omalizumab Biosimilars Sales Value by Application (%), 2025 vs 2032
Figure 63. Japan Omalizumab Biosimilars Sales Value (US$ Million), 2021–2032
Figure 64. Japan Omalizumab Biosimilars Sales Value by Type (%), 2025 vs 2032
Figure 65. Japan Omalizumab Biosimilars Sales Value by Application (%), 2025 vs 2032
Figure 66. South Korea Omalizumab Biosimilars Sales Value (US$ Million), 2021–2032
Figure 67. South Korea Omalizumab Biosimilars Sales Value by Type (%), 2025 vs 2032
Figure 68. South Korea Omalizumab Biosimilars Sales Value by Application (%), 2025 vs 2032
Figure 69. Southeast Asia Omalizumab Biosimilars Sales Value (US$ Million), 2021–2032
Figure 70. Southeast Asia Omalizumab Biosimilars Sales Value by Type (%), 2025 vs 2032
Figure 71. Southeast Asia Omalizumab Biosimilars Sales Value by Application (%), 2025 vs 2032
Figure 72. India Omalizumab Biosimilars Sales Value (US$ Million), 2021–2032
Figure 73. India Omalizumab Biosimilars Sales Value by Type (%), 2025 vs 2032
Figure 74. India Omalizumab Biosimilars Sales Value by Application (%), 2025 vs 2032
Figure 75. Omalizumab Biosimilars Industrial Chain
Figure 76. Omalizumab Biosimilars Manufacturing Cost Structure
Figure 77. Channels of Distribution (Direct Sales, and Distribution)
Figure 78. Bottom-up and Top-down Approaches for This Report
Figure 79. Data Triangulation
Figure 80. Key Executives Interviewed
KEY QUESTIONS ADDRESSED BY THE REPORT
What is the annual compound growth rate of the global Omalizumab Biosimilars market size from 2026 to 2032?
The annual compound growth rate of the global Omalizumab Biosimilars market is 11.2% 2026 to 2032.
What was the global market size of Omalizumab Biosimilars in 2032?
Which companies rank high in the global Omalizumab Biosimilars market?
Which region is expected to have the highest market share?
What was the global market size of Omalizumab Biosimilars in 2026?
Related Reports
Global Omalizumab Biosimilars Market Outlook, In‑Depth Analysis & Forecast to 2032
The global Omalizumab Biosimilars market is projected to grow from US$ 290 million in 2025 to US$ 598 million by 2032, at a CAGR of 11.2% (2026-2032), driven by critical product segments and diverse end‑use applications, while evolving U.S. tariff policies introduce trade‑cost volatility and supply‑chain uncertainty.
Published Date: 2026-04-16
Pages: 164
USD 4900.00
(Single User License)
Global Omalizumab Biosimilars Sales Market Report, Competitive Analysis and Regional Opportunities 2026-2032
The global Omalizumab Biosimilars market size was US$ 290 million in 2025 and is forecast to reach a readjusted size of US$ 598 million by 2032 with a CAGR of 11.2% during the forecast period 2026-2032.
Published Date: 2026-04-16
Pages: 142
USD 4250.00
(Single User License)
Global Omalizumab Biosimilars Market Research Report 2026
The global Omalizumab Biosimilars market was valued at US$ 290 million in 2025 and is anticipated to reach US$ 598 million by 2032, at a CAGR of 11.2% from 2026 to 2032.
Published Date: 2026-04-16
Pages: 120
USD 2900.00
(Single User License)
Omalizumab Biosimilars- Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
The global market for Omalizumab Biosimilars was estimated to be worth US$ million in 2024 and is forecast to a readjusted size of US$ million by 2031 with a CAGR of %during the forecast period 2025-2031.
Published Date: 2025-01-16
Pages: 119
USD 3950.00
(Single User License)
Global Omalizumab Biosimilars Market Research Report 2025
The global market for Omalizumab Biosimilars was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of %during the forecast period.
Published Date: 2025-01-16
Pages: 90
USD 2900.00
(Single User License)
Global Omalizumab Biosimilars Market Research Report 2024
Omalizumab is a medication used to treat asthma, nasal polyps, and urticaria. Omalizumab is a recombinant DNA-derived humanized IgG1k monoclonal antibody that specifically binds to free human immunoglobulin E (IgE) in the blood and interstitial fluid and to membrane-bound form of IgE (mIgE) on the surface of mIgE-expressing B lymphocytes. Unlike an ordinary anti-IgE antibody, it does not bind to IgE that is already bound by the high affinity IgE receptor (FcεRI) on the surface of mast cells, basophils, and antigen-presenting dendritic cells.
Published Date: 2024-01-20
Pages: 90
USD 2900.00
(Single User License)
Omalizumab Biosimilars - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030
Omalizumab is a medication used to treat asthma, nasal polyps, and urticaria. Omalizumab is a recombinant DNA-derived humanized IgG1k monoclonal antibody that specifically binds to free human immunoglobulin E (IgE) in the blood and interstitial fluid and to membrane-bound form of IgE (mIgE) on the surface of mIgE-expressing B lymphocytes. Unlike an ordinary anti-IgE antibody, it does not bind to IgE that is already bound by the high affinity IgE receptor (FcεRI) on the surface of mast cells, basophils, and antigen-presenting dendritic cells.
Published Date: 2024-01-11
Pages: 122
USD 3950.00
(Single User License)
Global Omalizumab Biosimilars Market Outlook, In‑Depth Analysis & Forecast to 2032
The global Omalizumab Biosimilars market is projected to grow from US$ 290 million in 2025 to US$ 598 million by 2032, at a CAGR of 11.2% (2026-2032), driven by critical product segments and diverse end‑use applications, while evolving U.S. tariff policies introduce trade‑cost volatility and supply‑chain uncertainty.
Published: 2026-04-16
Pages: 164
USD 4900.00 (Single User License)Global Omalizumab Biosimilars Sales Market Report, Competitive Analysis and Regional Opportunities 2026-2032
The global Omalizumab Biosimilars market size was US$ 290 million in 2025 and is forecast to reach a readjusted size of US$ 598 million by 2032 with a CAGR of 11.2% during the forecast period 2026-2032.
Published: 2026-04-16
Pages: 142
USD 4250.00 (Single User License)Global Omalizumab Biosimilars Market Research Report 2026
The global Omalizumab Biosimilars market was valued at US$ 290 million in 2025 and is anticipated to reach US$ 598 million by 2032, at a CAGR of 11.2% from 2026 to 2032.
Published: 2026-04-16
Pages: 120
USD 2900.00 (Single User License)Omalizumab Biosimilars- Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
The global market for Omalizumab Biosimilars was estimated to be worth US$ million in 2024 and is forecast to a readjusted size of US$ million by 2031 with a CAGR of %during the forecast period 2025-2031.
Published: 2025-01-16
Pages: 119
USD 3950.00 (Single User License)Global Omalizumab Biosimilars Market Research Report 2025
The global market for Omalizumab Biosimilars was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of %during the forecast period.
Published: 2025-01-16
Pages: 90
USD 2900.00 (Single User License)Global Omalizumab Biosimilars Market Research Report 2024
Omalizumab is a medication used to treat asthma, nasal polyps, and urticaria. Omalizumab is a recombinant DNA-derived humanized IgG1k monoclonal antibody that specifically binds to free human immunoglobulin E (IgE) in the blood and interstitial fluid and to membrane-bound form of IgE (mIgE) on the surface of mIgE-expressing B lymphocytes. Unlike an ordinary anti-IgE antibody, it does not bind to IgE that is already bound by the high affinity IgE receptor (FcεRI) on the surface of mast cells, basophils, and antigen-presenting dendritic cells.
Published: 2024-01-20
Pages: 90
USD 2900.00 (Single User License)Omalizumab Biosimilars - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030
Omalizumab is a medication used to treat asthma, nasal polyps, and urticaria. Omalizumab is a recombinant DNA-derived humanized IgG1k monoclonal antibody that specifically binds to free human immunoglobulin E (IgE) in the blood and interstitial fluid and to membrane-bound form of IgE (mIgE) on the surface of mIgE-expressing B lymphocytes. Unlike an ordinary anti-IgE antibody, it does not bind to IgE that is already bound by the high affinity IgE receptor (FcεRI) on the surface of mast cells, basophils, and antigen-presenting dendritic cells.
Published: 2024-01-11
Pages: 122
USD 3950.00 (Single User License)
CHOOSE LICENSE TYPE
USD 3950.00
USD 5925.00
USD 7900.00
Add to Cart
Buy Now
HAVE A QUESTION?
General Email:
REPORT COVERAGE
DESCRIPTION
OVERVIEW
MARKET SEGMENTATION
CHAPTER OUTLINE
QYRESEARCH'S STRENGTHS
TABLE OF CONTENTS
TABLE OF FIGURES
RLEATED REPORTS
INTEREST IN THIS REPORT?
Get A Free Sample
Request For Quotation
OR
NEED A CUSTOMIZED REPORT?
Customized Report
Request Sample
Pre-Order Enquiry
Add to Cart
Buy Now